Cargando…

Germline SNPs previously implicated as prognostic biomarkers do not associate with outcomes in intensively treated AML

[Figure: see text]

Detalles Bibliográficos
Autores principales:	Batcha, Aarif M. N., Buckup, Nele, Bamopoulos, Stefanos A., Jurinovic, Vindi, Rothenberg-Thurley, Maja, Gittinger, Hanna, Ksienzyk, Bianka, Dufour, Annika, Schneider, Stephanie, Kontro, Mika, Saad, Joseph, Heckmann, Caroline A., Sauerland, Cristina, Görlich, Dennis, Berdel, Wolfgang E., Wörmann, Bernhard J., Krug, Utz, Braess, Jan, Mansmann, Ulrich, Hiddemann, Wolfgang, Spiekermann, Karsten, Metzeler, Klaus H., Herold, Tobias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10036512/ https://www.ncbi.nlm.nih.gov/pubmed/36149944 http://dx.doi.org/10.1182/bloodadvances.2022007988

Ejemplares similares

A clinically applicable gene expression–based score predicts resistance to induction treatment in acute myeloid leukemia
por: Moser, Christian, et al.
Publicado: (2021)

A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia
por: Herold, Tobias, et al.
Publicado: (2018)

Mediation analysis reveals common mechanisms of RUNX1 point mutations and RUNX1/RUNX1T1 fusions influencing survival of patients with acute myeloid leukemia
por: Hornung, Roman, et al.
Publicado: (2018)

Allelic Imbalance of Recurrently Mutated Genes in Acute Myeloid Leukaemia
por: Batcha, Aarif M. N., et al.
Publicado: (2019)

Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
por: Rausch, Christian, et al.
Publicado: (2023)

P457: COMPLEX CARYOTYPE IS AN INDEPENDENT RISK FACTOR IN TP53-MUTATED AML
por: Rausch, Christian, et al.
Publicado: (2023)

P434: MYELODYSPLASIA-RELATED MUTATIONS IN THE NEW ELN CLASSIFICATION: DOES CLONAL SIZE PLAY A ROLE?
por: Rausch, Christian, et al.
Publicado: (2023)

Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older
por: Prassek, Victoria V., et al.
Publicado: (2018)

Clonal heterogeneity of FLT3-ITD detected by high-throughput amplicon sequencing correlates with adverse prognosis in acute myeloid leukemia
por: Schranz, Katrin, et al.
Publicado: (2018)

Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
por: Herold, Tobias, et al.
Publicado: (2020)

P446: COMPREHENSIVE CHARACTERIZATION OF DIFFERENTIAL GENE EXPRESSION AND ISOFORM USAGE IN SPLICING FACTOR-MUTATED ACUTE MYELOID LEUKEMIA USING LONG-READ SEQUENCING
por: Thieme, Susanne, et al.
Publicado: (2023)

The NPM1 Mutation Type Has No Impact on Survival in Cytogenetically Normal AML
por: Pastore, Friederike, et al.
Publicado: (2014)

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia
por: Rothenberg-Thurley, Maja, et al.
Publicado: (2018)

The clinical mutatome of core binding factor leukemia
por: Opatz, Sabrina, et al.
Publicado: (2020)

ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation
por: Hartmann, Luise, et al.
Publicado: (2016)

Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group
por: Lengfelder, Eva, et al.
Publicado: (2012)

P1402: ALTERATIONS OF HUMAN BONE MARROW NICHE IN CLONAL HEMATOPOIESIS AND AML
por: Dragieva, Y., et al.
Publicado: (2022)

Long-term follow-up of cytogenetically normal CEBPA-mutated AML
por: Pastore, Friederike, et al.
Publicado: (2014)

Clinical and preclinical characterization of CD99 isoforms in acute myeloid leukemia
por: Vaikari, Vijaya Pooja, et al.
Publicado: (2020)

Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantation
por: Kunadt, Desiree, et al.
Publicado: (2022)

Loss of KDM6A confers drug resistance in acute myeloid leukemia
por: Stief, Sophie M., et al.
Publicado: (2019)

Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning
por: Eckardt, Jan-Niklas, et al.
Publicado: (2022)

Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles
por: Eckardt, Jan-Niklas, et al.
Publicado: (2023)

Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study
por: Middeke, Jan M., et al.
Publicado: (2022)

Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia
por: Schemionek, Mirle, et al.
Publicado: (2015)

An NGS Workflow Blueprint for DNA Sequencing Data and Its Application in Individualized Molecular Oncology
por: Li, Jian, et al.
Publicado: (2016)

Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification
por: Eckardt, Jan-Niklas, et al.
Publicado: (2023)

Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction
por: Pohlen, Michele, et al.
Publicado: (2016)

Correction: Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk Prediction
por: Pohlen, Michele, et al.
Publicado: (2018)

The new and recurrent FLT3 juxtamembrane deletion mutation shows a dominant negative effect on the wild-type FLT3 receptor
por: Sandhöfer, Nadine, et al.
Publicado: (2016)

Plasticity in growth behavior of patients’ acute myeloid leukemia stem cells growing in mice
por: Ebinger, Sarah, et al.
Publicado: (2020)

Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia
por: Reiter, K, et al.
Publicado: (2018)

Improved outcomes in metastatic germ cell cancer: results from a large cohort study
por: Hentrich, Marcus, et al.
Publicado: (2020)

The Role of Therapeutic Leukapheresis in Hyperleukocytotic AML
por: Pastore, Friederike, et al.
Publicado: (2014)

Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F
por: Pastore, Friederike, et al.
Publicado: (2013)

Erufosine, a novel alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other antileukemic drugs
por: Fiegl, Michael, et al.
Publicado: (2007)

An Advanced Preclinical Mouse Model for Acute Myeloid Leukemia Using Patients' Cells of Various Genetic Subgroups and In Vivo Bioluminescence Imaging
por: Vick, Binje, et al.
Publicado: (2015)

Compartment-specific mutational landscape of clonal hematopoiesis
por: Hartmann, Luise, et al.
Publicado: (2022)

Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia
por: Alachkar, Houda, et al.
Publicado: (2014)

Clinical and molecular relevance of genetic variants in the non-coding transcriptome of patients with cytogenetically normal acute myeloid leukemia
por: Papaioannou, Dimitrios, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q028tedvf9v9fv6k1f1um61psu